Trial tests immune cells targeting HPV-16 cancers
Treatments studied
Part of Cancer, Digestive system, Ear, nose & throat, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer caused by HPV-16 that is metastatic (spread) or has come back or kept growing after treatment.
- Your tumor or blood test must confirm HPV-16 (done in a CLIA-certified lab).
- You must have the genetic marker HLA-A*02:01 (a blood test in a CLIA lab; you can start with broad HLA-A*02 testing but must confirm A*02:01 before cell collection).
- You are 18 or older and your health status is good enough for treatment (ECOG 0 or 1).
- You must have at least one measurable cancer spot on scans (per RECIST 1.1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental vaccines to boost the immune system against HPV 16. Healthy relatives of patients with HPV 16 cancer receive the vaccines, then donate blood cells for research.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack HPV-16 related cancers. It is for people with advanced solid tumors that have not responded to other treatments, and it aims to help shrink or control the cancer.
This study tests a new treatment using your own immune cells (called SCG142) that are specially trained to attack cancer cells linked to HPV 16 or 52. It may help people with advanced squamous cell cancers who have not gotten better with standard treatments.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.